3. Mach F, Baigent C, Catapano AL, Koskinas KC, Casula M, Badimon L,Chapman MJ, De Backer GG, Delgado V, Ference BA, et al; ESC Scientific Document Group. 2019 ESC/EAS Guidelines for the management of dyslipidaemi...
ASCVD Risk and Statin Use in PADatherosclerosiscardiovascular diseasecardiovascular eventshydroxymethylglutaryl-CoA reductase inhibitorsperipheral artery diseasesecondary preventiondoi:10.1016/j.jacc.2020.06.009Marc P. BonacaConnie N. HessJournal of the American College of Cardiology...
参考文献: [1] Mahmoud A, Almohtasib Y, Naeem A, et al. Abstract 4138221: Ezetimibe plus statin combination vs. double dose statin for patients with dyslipidemia and ASCVD risk: A Systematic Review and Meta-Analysis [...
Statin is a crucial intervention to fix dyslipidemia and reduce the ASCVD risk. Still, there are several regimens to achieve blood lipid level targets, including increasing the statin dose or adding ezetimibe to the statin used. However, the best option between the two regimens is still a ...
statin-treated patients who experience elevations in?liver?enzymes.Here, we define how a drug and associated adverse event isclassified as a signal when using each statistical test. Using the PRR, asignal is detected, if the count of co-occurrences ≥3 and thePRR≥2.0 with an associated x2...
Paul S. Jellinger, MD, MACE: Statin intolerance was bought up, and it's a good time to remind everyone about a recent study, a meta-analysis of 300,000 patients looking at statin intolerance, the so-called nocebo effect, which got a lot of publicity. When they dissected the true ...
users, despite adjustment including HDL-C.#Many US adults with borderline levels of TGs are at elevated ASCVD risk despite statin therapy, suggesting the need first for greater lifestyle modification efforts, and when indicated, evidence-based therapies known to reduce this residual ASCVD risk.doi...
ASCVD Risk Refinement With NT-proBNP for Statin Allocation Among Low- and Intermediate-Risk Individualsdoi:10.1161/CIRCULATIONAHA.124.071071atherosclerotic cardiovascular diseaseepidemiologyN-terminal pro-B-type natriuretic peptidepopulation-basedprimary prevention...
S1248Statin Utilization as a Function of Calculated ASCVD Risk in HCV-Infected Patientsdoi:10.14309/01.ajg.0000861632.83571.b9Spencer GobleHennepin County Medical Center (HCMC), Minneapolis, MN;Philippe NyemboHennepin County Medical Center (HCMC), Minneapolis, MN;Brian Goodroad...
[3] Han Y, et al. ODYSSEY EAST: Alirocumab efficacy and safety vs ezetimibe in high cardiovascular risk patients with hypercholesterolemia and on maximally tolerated statin in China, India, and Thailand[J].J Clin Lipidol. 202...